Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?

Biotech leader Gilead Sciences (GILD)  made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.Thanks to its durable drug pipeline for HIV and liver disease, Gilead's stock has been on a captivating ascension in the last two years, producing gains of +100% and hitting an all-time high of $157 a share in today’s trading session. Gilead’s Favorable Q4 resultsGilead posted Q4 sales of $7.92 billion, a 5% increase from $7.56 billion in the comparativ ...